October 2020 in “The American journal of gastroenterology” Para-aminobenzoic acid in hair supplements can cause autoimmune hepatitis.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
The patch effectively promotes hair growth for alopecia areata without pain.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
1 citations
,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
1 citations
,
March 2023 in “Skin” Baricitinib helps patients with severe alopecia areata regrow hair.
January 2017 in “Seoul National University Open Repository (Seoul National University)” AIMP1 can boost hair growth by increasing stem cell activity.
August 2024 in “Journal of the American Academy of Dermatology” Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.
May 2025 in “International Journal of Trichology” Baricitinib may effectively treat sudden hair whitening and regrowth in some cases.
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
2 citations
,
October 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” AIRE deficiency causes hair loss similar to alopecia areata in mice.
5 citations
,
July 2023 in “International Journal of Women’s Dermatology” Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
147 citations
,
August 2005 in “The Plant Cell” The TIP1 gene is crucial for normal plant cell growth in Arabidopsis.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
June 2025 in “British Journal of Dermatology” ALUDWIG can help standardize female hair loss assessment from a single image.
September 2025 in “The Open Dermatology Journal” The AI showed high accuracy in diagnosing skin conditions but needs improvement for immunological and infectious disorders.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.